Recent Updates
Recently added Catalysts

HER2 Expressing/Amplified Solid Tumors: one US-listed biotech with a clinical-stage programme

OncologyUncontestedData as of 2026-09-04

Competitors1in the clinic
Median market cap$1.9Buniverse median $1.20B
Allocated capital$484M$1.9B competing
Phase 3 or filed00 mid, 1 early
Pure plays0this indication only
Capital rank203/299crowding rank 208

HER2 Expressing/Amplified Solid Tumors is uncontested. Vir Biotechnology (VIR) is the only US-listed developer in the $100M to $20B band running a clinical programme here, with VIR-5818 in phase 1.

There is no public comparable to price it against. VIR spreads its $1.9B market cap across 4 indications, so $484M of it is allocated here.

Nothing here has reached Phase 3: 0 programmes in mid stage and 1 in early stage, so the field is still several years from a first approval.

$484M of allocated capital sits in HER2 Expressing/Amplified Solid Tumors, ranking it 203rd of 299 indications by the money committed to it.

Companies developing drugs for HER2 Expressing/Amplified Solid Tumors 1

TickerCompanyLead assetPhaseTrialsMarket capPure playIndicationsNext catalyst
VIRVir BiotechnologyVIR-5818Phase 11$1.9BNo4 31 Mar 2027

Sorted by phase, then by market capitalisation. Ticker links open the company profile.

Why HER2 Expressing/Amplified Solid Tumors counts as uncontested

Uncontested. One US-listed developer in the size band is running a clinical programme here, so there is no public comparable to price it against.

The map splits indications on two folds: six or more competitors counts as crowded, and a median company above $1.20B counts as richly priced. HER2 Expressing/Amplified Solid Tumors has one competitor and a median of $1.9B.

Oncology

Oncology holds $187B of the map's capital, 27.8% of the total, spread across 119 indications and 103 companies. 34 of those indications have more than one company competing.

See every Oncology indication on the map

Related indications in Oncology

Hormone-refractory Prostate Adenocarcinoma1 company · $484M · median $1.9BUncontestedMetastatic Hepatocellular Carcinoma1 company · $495M · median $1.5BUncontestedHR+/HER2- Breast Cancer1 company · $469M · median $939MUncontestedTriple Negative Metastatic Breast Cancer1 company · $448M · median $1.8BUncontestedEwing Sarcoma1 company · $448M · median $1.8BUncontestedChondrosarcoma1 company · $448M · median $1.8BUncontestedMultiple Myeloma3 companies · $421M · median $460MOrphan cornerT-cell Lymphoma1 company · $411M · median $1.2BUncontested

HER2 Expressing/Amplified Solid Tumors pipeline questions

Which biotech companies are developing drugs for HER2 Expressing/Amplified Solid Tumors?

Vir Biotechnology (VIR, VIR-5818, Phase 1). Those are the 1 US-listed developer in the $100M to $20B market cap band with a clinical-stage programme in HER2 Expressing/Amplified Solid Tumors.

How advanced is the HER2 Expressing/Amplified Solid Tumors pipeline?

Of the 1 clinical-stage programme in HER2 Expressing/Amplified Solid Tumors, 0 are in Phase 3 or filed, 0 are in mid-stage development and 1 is in early-stage development.

Is anyone else developing a drug for HER2 Expressing/Amplified Solid Tumors?

No. VIR is the only US-listed company in the $100M to $20B market cap band with a clinical-stage programme in HER2 Expressing/Amplified Solid Tumors, which is why the indication is classified as uncontested.

When is the next HER2 Expressing/Amplified Solid Tumors catalyst?

The next dated catalyst in HER2 Expressing/Amplified Solid Tumors is VIR on 31 Mar 2027. 1 dated event across the field fall in the next 12 months.

How this page is built

  • Universe is US-listed drug developers with a $100M to $20B market capitalisation, identified by SEC SIC code 2833, 2834 or 2836 or by a pharmaceutical or biotechnology industry classification, less a reviewed exclusion list of contract research organisations, device and diagnostics makers and diversified generics manufacturers.
  • An asset attributed to three or more different companies is treated as shared standard of care rather than any one company’s programme and excluded. Pembrolizumab alone appears under 21 tickers in raw trial data.
  • A programme counts only where at least one industry-sponsored trial supports it, so investigator-initiated academic studies of third-party drugs are excluded.

Allocated capital divides each company’s market capitalisation evenly across the indications it is running clinical programmes in, so every dollar of the universe is counted exactly once. Total market capitalisation competing counts a company in each of its indications and therefore sums to more than the universe.

Third-party market size estimates are not used anywhere on this page. Approved incumbents are excluded from competitor counts, and companies above $20B are outside the universe by construction.

Back to the disease map